Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Boundless Bio, Inc.BOLD · Entity 7063 | Director · President & CEO | January 23, 2026 | January 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Boundless Bio, Inc.
Report date January 23, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2036-01-22 | Direct | 600,000 |
Reported balance
After 2026-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-23 · Grant · Acquired 600,000 · Balance 600,000 F1: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ignyta, Inc.
Report date February 08, 2018 · Filed February 12, 2018
Section 16 reporting ended · disclosed 2018-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 1
1 source rowRow 1 · 2018-02-08 · Disposition to issuer · Disposed 165,748 · Balance 0 F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2023-09-09 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-08 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2023-12-16 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-08 · Disposition to issuer · Disposed 250,000 · Balance 0 F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.58 · Expires 2025-01-07 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-08 · Disposition to issuer · Disposed 48,000 · Balance 0 F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2027-01-04 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-02-08 · Disposition to issuer · Disposed 60,000 · Balance 0 F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger").
F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2026 Filed Jan 26, 2026 12:00 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001193125-26-021655 · ownership.xml · derivative · entry 1 Hornby Zachary · CIK 0001602227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2036-01-22 F1 · derivative.exercise_date: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter. Read SEC document |
| January 22, 2025 Filed Jan 23, 2025 21:05 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 295,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0000950170-25-008318 · ownership.xml · derivative · entry 1 Hornby Zachary · CIK 0001602227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,000 Underlying: Common Stock · 295,000 shares Expires 2035-01-21 F1 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on February 1, 2025. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 23:10 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 162,343 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099306 · ownership.xml · derivative · entry 8 Hornby Zachary · CIK 0001602227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,343 Underlying: Common Stock · 162,343 shares Expires 2034-03-26 F6 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged. F5 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 23:10 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 257,207 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099306 · ownership.xml · derivative · entry 7 Hornby Zachary · CIK 0001602227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,207 Underlying: Common Stock · 257,207 shares Expires 2034-02-14 F6 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 23:10 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 471,282 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099306 · ownership.xml · derivative · entry 6 Hornby Zachary · CIK 0001602227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471,282 Underlying: Common Stock · 471,282 shares Expires 2033-06-12 F6 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 23:10 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 256,410 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099306 · ownership.xml · derivative · entry 5 Hornby Zachary · CIK 0001602227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,410 Underlying: Common Stock · 256,410 shares Expires 2031-06-06 F6 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on July 7, 2021. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 23:10 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 162,343 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-099306 · ownership.xml · derivative · entry 4 Hornby Zachary · CIK 0001602227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 162,343 shares Expires 2034-03-26 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged. F5 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 23:10 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 257,207 | Not disclosed Strike: $8.19 | Not disclosed |
DisclosureSEC source: 0000950170-24-099306 · ownership.xml · derivative · entry 3 Hornby Zachary · CIK 0001602227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 257,207 shares Expires 2034-02-14 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 23:10 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 471,282 | Not disclosed Strike: $4.10 | Not disclosed |
DisclosureSEC source: 0000950170-24-099306 · ownership.xml · derivative · entry 2 Hornby Zachary · CIK 0001602227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 471,282 shares Expires 2033-06-12 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 23:10 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 256,410 | Not disclosed Strike: $4.10 | Not disclosed |
DisclosureSEC source: 0000950170-24-099306 · ownership.xml · derivative · entry 1 Hornby Zachary · CIK 0001602227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 256,410 shares Expires 2031-06-06 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on July 7, 2021. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:30 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 162,343 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-038696 · ownership.xml · derivative · entry 1 Hornby Zachary · CIK 0001602227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,343 Underlying: Common Stock · 162,343 shares Expires 2034-03-26 F1 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:31 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-18-009145 · doc4.xml · derivative · entry 5 Hornby Zachary · CIK 0001602227 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2027-01-04 F2 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:31 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $6.58 | $0.00 |
DisclosureSEC source: 0001209191-18-009145 · doc4.xml · derivative · entry 4 Hornby Zachary · CIK 0001602227 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,000 shares Expires 2025-01-07 F2 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:31 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009145 · doc4.xml · derivative · entry 3 Hornby Zachary · CIK 0001602227 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2023-12-16 F2 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:31 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001209191-18-009145 · doc4.xml · derivative · entry 2 Hornby Zachary · CIK 0001602227 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-09-09 F2 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:31 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerCommon Stock | 165,748 | $27.00 | $4,475,196.00 |
DisclosureSEC source: 0001209191-18-009145 · doc4.xml · nonDerivative · entry 1 Hornby Zachary · CIK 0001602227 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). Read SEC document |
| December 26, 2017 Filed Dec 29, 2017 02:35 UTC | Ignyta, Inc. RXDX · Entity 169521 | Tax withholdingCommon Stock | 18,552 | $26.70 | $495,338.40 |
DisclosureSEC source: 0000899243-17-029702 · doc4.xml · nonDerivative · entry 1 Hornby Zachary · CIK 0001602227 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,748 Read SEC document |
| December 22, 2017 Filed Dec 23, 2017 02:45 UTC | Ignyta, Inc. RXDX · Entity 169521 | GrantCommon Stock | 37,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067160 · doc4.xml · nonDerivative · entry 1 Hornby Zachary · CIK 0001602227 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,300 F1 · shares: Represents the grant of restricted stock units to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units will vest as to 25% of the shares underlying each award on each anniversary of the Grant Date, subject to the Reporting Person's continues service with the Company through the vesting date. Read SEC document |
| May 03, 2017 Filed May 5, 2017 18:25 UTC | Ignyta, Inc. RXDX · Entity 169521 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001209191-17-030260 · doc4.xml · derivative · entry 6 Hornby Zachary · CIK 0001602227 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 10,000 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: As of May 3, 2017 and prior to this transaction, 44,791 shares of common stock subject to the option vested. Approximately 1,041 shares of common stock subject to the option vest on the ninth day of each month until September 9, 2017. Read SEC document |
| May 03, 2017 Filed May 5, 2017 18:25 UTC | Ignyta, Inc. RXDX · Entity 169521 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,389 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-17-030260 · doc4.xml · derivative · entry 5 Hornby Zachary · CIK 0001602227 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,389 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| May 03, 2017 Filed May 5, 2017 18:25 UTC | Ignyta, Inc. RXDX · Entity 169521 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,083 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001209191-17-030260 · doc4.xml · derivative · entry 4 Hornby Zachary · CIK 0001602227 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2022-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| May 03, 2017 Filed May 5, 2017 18:25 UTC | Ignyta, Inc. RXDX · Entity 169521 | Exercise / conversionCommon Stock | 10,000 | $1.02 | $10,200.00 |
DisclosureSEC source: 0001209191-17-030260 · doc4.xml · nonDerivative · entry 3 Hornby Zachary · CIK 0001602227 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2017 Filed May 5, 2017 18:25 UTC | Ignyta, Inc. RXDX · Entity 169521 | Exercise / conversionCommon Stock | 1,389 | $0.60 | $833.40 |
DisclosureSEC source: 0001209191-17-030260 · doc4.xml · nonDerivative · entry 2 Hornby Zachary · CIK 0001602227 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2017 Filed May 5, 2017 18:25 UTC | Ignyta, Inc. RXDX · Entity 169521 | Exercise / conversionCommon Stock | 2,083 | $0.57 | $1,187.31 |
DisclosureSEC source: 0001209191-17-030260 · doc4.xml · nonDerivative · entry 1 Hornby Zachary · CIK 0001602227 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 23:46 UTC | Ignyta, Inc. RXDX · Entity 169521 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-17-002763 · doc4.xml · derivative · entry 1 Hornby Zachary · CIK 0001602227 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: The option is exercisable as it vests. 25% of the shares subject to the option vest on January 5, 2018, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.